File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.bmc.2014.06.027
- Scopus: eid_2-s2.0-84906937206
- PMID: 25043312
- WOS: WOS:000341293300047
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides
Title | Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides |
---|---|
Authors | Laufer, RadoslawNg, GraceLiu, YongPatel, Narendra Kumar B.Edwards, Louise G.Lang, YunhuiLi, Sze WanFeher, MiklosAwrey, Don E.Leung, GenieBeletskaya, IrinaPlotnikova, OlgaMason, Jacqueline M.Hodgson, RichardWei, XinMao, GuodongLuo, XunyiHuang, PingGreen, ErinKiarash, RezaLin, Dan Chi ChiaHarris-Brandts, MareesBan, FuqiangNadeem, VincentMak, Tak W.Pan, Guohua J.Qiu, WeiChirgadze, Nickolay Y.Pauls, Henry W. |
Keywords | Indazolyl benzenesulfonamide antimitotic agents Tyrosine Threonine Kinase (TTK) Mitotic kinase Anticancer Monopolar Spindle 1 kinase (Mps1) |
Issue Date | 2014 |
Citation | Bioorganic and Medicinal Chemistry, 2014, v. 22, n. 17, p. 4968-4997 How to Cite? |
Abstract | TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50 = 3.6 nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described. © 2014 Elsevier Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/292843 |
ISSN | 2023 Impact Factor: 3.3 2023 SCImago Journal Rankings: 0.614 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Laufer, Radoslaw | - |
dc.contributor.author | Ng, Grace | - |
dc.contributor.author | Liu, Yong | - |
dc.contributor.author | Patel, Narendra Kumar B. | - |
dc.contributor.author | Edwards, Louise G. | - |
dc.contributor.author | Lang, Yunhui | - |
dc.contributor.author | Li, Sze Wan | - |
dc.contributor.author | Feher, Miklos | - |
dc.contributor.author | Awrey, Don E. | - |
dc.contributor.author | Leung, Genie | - |
dc.contributor.author | Beletskaya, Irina | - |
dc.contributor.author | Plotnikova, Olga | - |
dc.contributor.author | Mason, Jacqueline M. | - |
dc.contributor.author | Hodgson, Richard | - |
dc.contributor.author | Wei, Xin | - |
dc.contributor.author | Mao, Guodong | - |
dc.contributor.author | Luo, Xunyi | - |
dc.contributor.author | Huang, Ping | - |
dc.contributor.author | Green, Erin | - |
dc.contributor.author | Kiarash, Reza | - |
dc.contributor.author | Lin, Dan Chi Chia | - |
dc.contributor.author | Harris-Brandts, Marees | - |
dc.contributor.author | Ban, Fuqiang | - |
dc.contributor.author | Nadeem, Vincent | - |
dc.contributor.author | Mak, Tak W. | - |
dc.contributor.author | Pan, Guohua J. | - |
dc.contributor.author | Qiu, Wei | - |
dc.contributor.author | Chirgadze, Nickolay Y. | - |
dc.contributor.author | Pauls, Henry W. | - |
dc.date.accessioned | 2020-11-17T14:57:20Z | - |
dc.date.available | 2020-11-17T14:57:20Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Bioorganic and Medicinal Chemistry, 2014, v. 22, n. 17, p. 4968-4997 | - |
dc.identifier.issn | 0968-0896 | - |
dc.identifier.uri | http://hdl.handle.net/10722/292843 | - |
dc.description.abstract | TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50 = 3.6 nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described. © 2014 Elsevier Ltd. All rights reserved. | - |
dc.language | eng | - |
dc.relation.ispartof | Bioorganic and Medicinal Chemistry | - |
dc.subject | Indazolyl benzenesulfonamide | - |
dc.subject | antimitotic agents | - |
dc.subject | Tyrosine Threonine Kinase (TTK) | - |
dc.subject | Mitotic kinase | - |
dc.subject | Anticancer | - |
dc.subject | Monopolar Spindle 1 kinase (Mps1) | - |
dc.title | Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.bmc.2014.06.027 | - |
dc.identifier.pmid | 25043312 | - |
dc.identifier.scopus | eid_2-s2.0-84906937206 | - |
dc.identifier.volume | 22 | - |
dc.identifier.issue | 17 | - |
dc.identifier.spage | 4968 | - |
dc.identifier.epage | 4997 | - |
dc.identifier.eissn | 1464-3391 | - |
dc.identifier.isi | WOS:000341293300047 | - |
dc.identifier.issnl | 0968-0896 | - |